کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
11014382 | 1794034 | 2018 | 12 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
Gene Expression Signature for Prediction of Golimumab Response in a Phase 2a Open-Label Trial of Patients With Ulcerative Colitis
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
IBDAUCROCGene signature - امضای ژنInflammatory bowel disease - بیماریهای التهابی رودهconfidence interval - فاصله اطمینانTranscriptomics - متن ترانهarea under the receiver operating characteristic curve - محدوده تحت منحنی مشخصه عملکرد گیرندهMPs - نمایندگان مجلسPrediction of response - پیش بینی پاسخUlcerative colitis - کولیت اولسراتیو
موضوعات مرتبط
علوم پزشکی و سلامت
پزشکی و دندانپزشکی
بیماریهای گوارشی
پیش نمایش صفحه اول مقاله
چکیده انگلیسی
Golimumab, a tumor necrosis factor antagonist, is an effective treatment for patients with moderate-to-severe ulcerative colitis (UC); however, more than 50% of initial responders lose their response to the drug within the first year of therapy. A gene expression signature identified in colon biopsies collected before treatment was associated with response to infliximab, and was subsequently refined to associate with mucosal healing in response to golimumab. We performed a phase 2a open-label study of 103 golimumab-treated patients with moderate-to-severe UC to test whether the baseline gene expression signature could be used to predict which patients would achieve mucosal healing, clinical response, and clinical remission at weeks 6 and 30 of treatment. The gene expression signature identified patients who went on to achieve mucosal healing at treatment week 6 with an area under the receiver operating characteristic curve (AUCROC) of 0.688 (P = .002) and at week 30 with an AUCROC of 0.671 (P = .006). The signature identified patients with mucosal healing with 87% sensitivity, but only 34% specificity, limiting its clinical utility. The baseline gene expression signature did not identify patients who went on to achieve clinical remission or clinical response with statistical significance. Further studies are needed to identify biomarkers that can be used to predict which patients with UC will respond to treatment with anti-tumor necrosis factor agents. ClinicalTrials.gov no: NCT01988961.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Gastroenterology - Volume 155, Issue 4, October 2018, Pages 1008-1011.e8
Journal: Gastroenterology - Volume 155, Issue 4, October 2018, Pages 1008-1011.e8
نویسندگان
Shannon E. Telesco, Carrie Brodmerkel, Hongyan Zhang, Lilianne (Lee-Lian) Kim, Jewel Johanns, Abhijit Mazumder, Katherine Li, Frédéric Baribaud, Mark Curran, Richard Strauss, Bethany Paxson, Scott Plevy, Timothy Davison, Laura Knight, Sian Dibben,